ABT
HealthcareAbbott Laboratories
Price Chart
Market Data
Financials
XBRL · SEC EDGAR2007–2025(19yr)| Metric | FY 2007 | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025Latest | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.9B | $29.5B | $30.8B | $35.2B | $38.9B | $39.9B | $21.8B | $20.2B | $20.4B | $20.9B | $27.4B | $30.6B | $31.9B | $34.6B | $43.1B | $43.7B | $40.1B | $42.0B | $44.3B | +5.7% |
| Gross Profit | $14.5B | $16.9B | $17.6B | $20.5B | $23.3B | $24.8B | $11.8B | $11.0B | $11.7B | $11.8B | $15.0B | $17.9B | $18.7B | $19.6B | $24.5B | $24.5B | $22.1B | $23.2B | $25.0B | +7.6% |
| Gross Margin | 55.9% | 57.3% | 57.1% | 58.3% | 60.0% | 62.1% | 54.0% | 54.5% | 57.1% | 56.4% | 54.7% | 58.4% | 58.5% | 56.6% | 57.0% | 56.1% | 55.2% | 55.4% | 56.4% | +1.0pp |
| Operating Income | $4.6B | $5.7B | $6.2B | $6.1B | $5.8B | $8.1B | $2.6B | $2.6B | $2.9B | $3.2B | $1.7B | $3.6B | $4.5B | $5.4B | $8.4B | $8.4B | $6.5B | $6.8B | $8.1B | +18.0% |
| Operating Margin | 17.7% | 19.3% | 20.3% | 17.3% | 14.8% | 20.3% | 12.0% | 12.8% | 14.1% | 15.3% | 6.3% | 11.9% | 14.2% | 15.5% | 19.6% | 19.2% | 16.2% | 16.3% | 18.2% | +1.9pp |
| Net Income | $3.6B | $4.9B | $5.7B | $4.6B | $4.7B | $6.0B | $2.6B | $2.3B | $4.4B | $1.4B | $477.0M | $2.4B | $3.7B | $4.5B | $7.1B | $6.9B | $5.7B | $13.4B | $6.5B | -51.3% |
| Net Margin | 13.9% | 16.5% | 18.7% | 13.2% | 12.2% | 15.0% | 11.8% | 11.3% | 21.7% | 6.7% | 1.7% | 7.7% | 11.6% | 13.0% | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% | -17.2pp |
| Free Cash Flow | — | — | — | — | $7.5B | $7.5B | $2.2B | $2.6B | $1.9B | $2.1B | $4.4B | $4.9B | $4.5B | $5.7B | $8.6B | $7.8B | $5.1B | $6.4B | $7.4B | +16.4% |
| FCF Margin | — | — | — | — | 19.2% | 18.9% | 10.0% | 12.8% | 9.1% | 10.0% | 16.2% | 16.0% | 14.1% | 16.5% | 20.1% | 17.9% | 12.6% | 15.1% | 16.7% | +1.5pp |
| EPS (Diluted) | $2.31 | $3.12 | $3.69 | $2.96 | $3.01 | $3.72 | $1.62 | $1.49 | $2.92 | $0.94 | $0.27 | $1.33 | $2.06 | $2.50 | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 | -51.3% |
1. THE BIG PICTURE
Abbott is a study in corporate rebalancing. By leveraging a massive global footprint to stabilize its base, Abbott Laboratories is aggressively shifting its weight toward high-growth medical technology—specifically in diabetes care and electrophysiology—to replace waning COVID-19 diagnostic revenues.
2. WHERE THE RISKS HIT HARDEST
Abbott’s "steady cadence of important product approvals" (14A Proxy) is directly threatened by manufacturing complexity. In an industry where equipment malfunctions or failure to meet exacting specifications can lead to discarded batches and facility shutdowns, the very innovation that drives growth creates a high-stakes operational bottleneck (RISKS). Furthermore, the strategic advantage of operating in 160 countries (10-K Item 1) is vulnerable to supply chain disruptions; macroeconomic pressures like labor shortages and inflation have historically increased raw material costs, which can immediately erode the profitability of these global product lines (RISKS).
3. WHAT THE NUMBERS SAY TOGETHER
The financial data reveals a business in a state of high-velocity transition. While total sales grew 4.4% in the most recent quarter, the Medical Devices segment surged 12.3%, led by a 15% jump in Diabetes Care (8-K). This internal momentum is masked by a 2.5% decline in Diagnostics as COVID-related testing continues to evaporate, and a temporary 8.9% drop in Nutrition sales following "strategic price actions" (8-K). Despite these shifts, Abbott maintains an operating margin of 17.6%, placing it in the middle of its peer group (XBRL). Market sentiment remains steady, with short interest at a low 1.0% of the float, suggesting investors view the current segment volatility as a controlled evolution rather than a structural decline (Supplemental Signals).
4. IS IT WORTH IT AT THIS PRICE?
At 17.7x Forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations, Abbott trades at a modest 9% discount to the peer median of 19.4x. According to CAPM analysis, this price implies the market is looking for roughly 2.9% long-term growth. This expectation appears achievable, if not cautious, given that management has guided for 2026 organic sales growth between 6.5% and 7.5% (8-K). However, the discount to peers like Johnson & Johnson (26.5% net margin) is justified by Abbott’s lower 14.7% net margin and its 56.1% gross margin, which ranks 5th among its six primary peers (XBRL). The primary factor that could compress this valuation further is the $20 billion in new debt for the Exact Sciences acquisition, which threatens to significantly alter a balance sheet that currently enjoys a low 0.8x net leverage (RISKS, CAPM analysis).
5. WHAT WOULD CHANGE THIS VIEW?
- Cautious if the $20 billion debt assumption for the Exact Sciences acquisition leads to a credit rating downgrade or if integration costs materially exceed the "significant expenses" warned of in filings (RISKS).
- Constructive if the Nutrition segment shows a volume-driven recovery in 2026, proving that the recent 8.9% sales decline was a successful strategic trade-off for future market share (8-K).
- Constructive if the Medical Devices segment maintains double-digit growth, particularly as new products like the Volt® Pulsed Field Ablation System enter the mix (10-K Item 1, 8-K).
6. BOTTOM LINE
Structural Advantage: A diversified healthcare model that uses a massive, stable global distribution network for nutrition and pharmaceuticals to fund high-margin, "first-of-its-kind" medical device innovation. Bottom Line: Abbott is a well-hedged healthcare giant currently priced for modest growth, making it an attractive play for investors who believe its device pipeline will outperform low market expectations.
1. Top 5 Material Risks
- Global Supply Chain Disruptions: Abbott Laboratories relies on a large, complex supply chain; macroeconomic conditions like inflation and labor shortages have historically impacted the cost and availability of raw materials, directly affecting results of operations.
- Acquisition and Integration Challenges: Pursuing strategic acquisitions or spin-offs may lead to significant expenses, the assumption of unknown liabilities, or the failure to realize expected benefits, which can negatively impact profitability and credit ratings.
- Cybersecurity and Data Privacy: As a multinational entity, Abbott Laboratories is a target for malware and hacking; a significant incident could lead to lost revenue, regulatory fines, and manufacturing disruptions, while breaches of protected health information carry similar financial and reputational risks.
- Research and Development Failure: Abbott Laboratories must commit substantial funds to R&DR&DResearch & Development — spending on creating new products or technologies without assurance of commercial success; failure to launch new products or the obsolescence of existing ones due to competitor innovation threatens future revenue and profitability.
- Manufacturing Complexity: The highly exacting nature of manufacturing medical products means that equipment malfunctions or failure to meet specifications can lead to discarded batches, production stoppages, and recall costs, all of which threaten revenues and profitability.
2. Company-Specific Risks
- Exact Sciences Acquisition Debt: Abbott Laboratories plans to fund the acquisition with approximately $20 billion in new borrowings, which, when added to the $12.9 billion in consolidated indebtedness as of December 31, 2025, could lead to a deterioration of credit ratings and increased borrowing costs.
- Data-Driven Healthcare Model: Abbott Laboratories is investing in new business models focused on data-centric prevention and treatment strategies; failure to maintain these models or their obsolescence due to competitor innovation could cause a decline in revenue and profitability.
- Infant Formula Recall Exposure: Abbott Laboratories’s history of voluntary recalls and consent decrees, such as the 2022 recall of powder infant formula and subsequent FDA consent decree, highlights the risk of total or partial production shutdowns at specific facilities.
3. Regulatory/Legal Risks
- Government Benefit Programs: Abbott Laboratories is subject to anti-kickback and false claims laws; violations can result in substantial fines, imprisonment, or exclusion from participation in U.S. government healthcare programs like Medicare and Medicaid.
- Intellectual Property Litigation: Abbott Laboratories is frequently subject to patent infringement claims from competitors; a successful claim could result in significant damages or an injunction preventing the sale or manufacture of specific products.
- Healthcare Reform: Legislative changes, such as those stemming from the Affordable Care Act, or adverse decisions regarding product coverage and reimbursement, can directly impact the demand for and pricing of products.
- Tax Law Evolution: Changes in international tax rules, such as the two-pillared plan proposed by the OECD, could materially adversely affect the effective tax rate and financial condition of Abbott Laboratories.
4. Financial Impact Map
- Global Supply Chain Disruptions → Results of Operations → Increased costs and reduced availability of raw materials and supplies.
- Acquisition and Integration Challenges → Profitability and Liquidity → Incurrence of acquisition-related charges, amortization of intangible assets, and increased interest expense.
- Cybersecurity and Data Privacy → Revenue and Operating Expenses → Lost revenue from product availability issues and increased costs from regulatory fines and litigation.
- Research and Development Failure → Revenue and Profitability → Decline in sales due to product obsolescence or failure to reach the market.
- Manufacturing Complexity → Revenues and Profitability → Lost revenue from production stoppages and increased costs from product recalls and liability claims.
Recent Filings
| Form | Filed | Period |
|---|---|---|
| 10-K | Feb 2026 | Dec 2025 |
| 8-K | Jan 2026 | — |
| 10-Q | Oct 2025 | Sep 2025 |
| 14A | Mar 2025 | — |
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
Abbott Laboratories participates in Whoop's $575M Series G funding round
- ▸Participated in Whoop's $575M Series G funding round
- ▸Strategic move into consumer-facing digital health wearables
- ▸Aims to integrate medical device expertise with wearable health data
- ▸Potential expansion into software and recurring subscription revenue models
- ▸ABT shares currently trading 23% below analyst consensus price target
Whoop Raises $575M at $10.1B Valuation, Reports 103% Revenue Growth
- ▸Raised $575M in Series G funding at $10.1B valuation
- ▸Revenue run rate reached $1.1B, up 103% YoY
- ▸Surpassed 2.5 million total members
- ▸Achieved cash flow positive status in 2025
- ▸International sales account for 60% of total revenue
Whoop valuation triples to $10.1 billion following $575 million Series G funding round
- ▸Raised $575 million in Series G funding
- ▸Valuation reached $10.1 billion, nearly triple previous $3.6 billion
- ▸Total funding raised to date approximately $900 million
- ▸Exited previous year at $1.1 billion bookings run rate, +103% YoY
- ▸Abbott Laboratories joined as a strategic investor
Whoop valuation hits $10B following $575M funding round ahead of potential IPO
- ▸Valuation exceeds $10B following $575M funding round
- ▸Bookings grew 103% YoY with $1.1B run rate at end of 2025
- ▸Company reports 2.5 million active members
- ▸Operating cash flow positive status achieved
- ▸Abbott Laboratories participated in funding round
Whoop raises $575M in Series G funding at $10.1B valuation, eyes future IPO
- ▸Raised $575M in Series G funding at $10.1B valuation
- ▸Bookings grew 103% YoY with $1.1B run rate exiting 2025
- ▸Business achieved operating cash flow positive status in 2025
- ▸Company reports 2.5 million active members
- ▸Whoop MG model received FDA clearance for ECG and blood pressure monitoring
Abbott integrates precision oncology portfolio into Flatiron Health's OncoEMR clinical platform
- ▸Integrated precision oncology tests into Flatiron Health's OncoEMR platform
- ▸Access provided to 1,600 community cancer centers and 4,700 providers
- ▸Tests include Oncotype DX, OncoExTra, Oncodetect, and Riskguard
- ▸Projects $55.6B revenue and $10B earnings by 2029
- ▸Requires 7.9% annual revenue growth to meet long-term targets
Abbott Laboratories completes acquisition of Exact Sciences to expand cancer screening diagnostics
- ▸Abbott Laboratories completed acquisition of Exact Sciences
- ▸Exact Sciences now operates as a wholly-owned subsidiary of Abbott
- ▸Acquisition targets $60 billion US cancer screening and precision oncology market
- ▸Deal adds new growth vertical to Abbott's high-single-digit growth outlook
- ▸Integration aims to advance preventative, predictive, and personalized diagnostic capabilities
Abbott completes acquisition of Exact Sciences to enter $60B cancer screening market
- ▸Acquisition of Exact Sciences completed, now a wholly owned subsidiary
- ▸Establishes leadership in $60B U.S. cancer screening and precision oncology segments
- ▸Adds Cologuard and Oncotype DX to Abbott's diagnostics portfolio
- ▸Exact Sciences shares delisted from Nasdaq effective March 20, 2026
- ▸Transaction adds new growth vertical to Abbott's high-single-digit growth expectations
Synlait H1 net loss NZ$80.6M vs profit NZ$4.8M; net debt jumps 88%
- ▸H1 net loss NZ$80.6M (US$47.1M) vs prior year profit NZ$4.8M
- ▸EBITDA loss NZ$35M compared to prior year profit NZ$63M
- ▸Revenue +3.5% to NZ$949M
- ▸Net debt increased 88% to NZ$472.1M
- ▸North Island asset divestment to Abbott on track for completion next week
Abbott completes acquisition of Exact Sciences to expand cancer diagnostics portfolio
- ▸Acquisition of Exact Sciences completed, now a wholly owned subsidiary
- ▸Exact Sciences shares delisted from Nasdaq effective March 20, 2026
- ▸Adds leadership in $60B U.S. cancer screening and precision oncology market
- ▸Portfolio includes Cologuard, Oncotype DX, Oncodetect, and Cancerguard tests
- ▸Transaction adds new growth vertical to Abbott's high-single-digit growth expectations